Page 8 - Motor Function News Today : Breaking News, Live Updates & Top Stories | Vimarsana

iii MISSISSAUGA, ON, April 15, 2021 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has granted EVRYSDI Ⓡ (risdiplam) market authorization for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older. iii EVRYSDI works by helping the body make more of a protein called, SMN protein. EVRYSDI increases and sustains the amount of SMN protein in the body, which helps to treat SMA. It is the first medicine for SMA that can be taken at home and is administered once daily by mouth or feeding tube. iii The Health Canada approval of EVRYSDI is a welcome addition in our ability to treat SMA. It is an efficacious treatment that significantly increases survival motor neuron (SMN) protein in SMA patients, said Dr. Hugh McMillan, Pediatric Neurologist at the Children s Hospital of Eastern Ontario. We now have an additional and convenient treatment option with EVRYSDI, as it s the first at-home and oral option for patients

Hugh mcmillanAmy loignonJennifer motaNeuromuscular networkRoche limited canadaToddler developmentHealth canadaHealth canada approvalRoche canadaPediatric neurologistBayley scalesThird editionMotor functionSpinal muscular atrophyDiabetes careMuscular atrophy